Inotropic agents in the treatment of cardiogenic shock.
D002303:Cardiac Output, Low / Q000150:complications; D002305:Cardiac Tamponade / Q000150:complications; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002395:Catecholamines / Q000627:therapeutic use*; D004070:Digitalis; D004280:Dobutamine / Q000627:therapeutic use*; D004298:Dopamine / Q000627:therapeutic use*; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use*; D008680:Metaraminol / Q000627:therapeutic use; D008729:Methoxamine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications*; D009638:Norepinephrine / Q000627:therapeutic use; D010656:Phenylephrine / Q000627:therapeutic use; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011655:Pulmonary Embolism / Q000150:complications; D012770:Shock, Cardiogenic / Q000188:drug therapy*
D002316:Cardiotonic Agents; D002395:Catecholamines; D010656:Phenylephrine; D004280:Dobutamine; D008680:Metaraminol; D005934:Glucagon; D008729:Methoxamine; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine